公开(公告)号：US20240093265A1

公开(公告)日：2024-03-21

申请号：US17942555

申请日：2022-09-12

申请人： Concert Pharmaceuticals, Inc.

发明人： Roger Tung

IPC分类号： C12Q1/28 ,  A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07B59/00 ,  C07D221/28 ,  C07D471/08 ,  G01N33/49 ,  G01N33/493

CPC分类号： C12Q1/28 ,  A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07B59/002 ,  C07D221/28 ,  C07D471/08 ,  G01N33/491 ,  G01N33/493

摘要： This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

公开(公告)号：US11473123B2

公开(公告)日：2022-10-18

申请号：US17120880

申请日：2020-12-14

申请人： Concert Pharmaceuticals, Inc.

发明人： Roger Tung

IPC分类号： A61K31/4748 ,  C12Q1/28 ,  C07B59/00 ,  C07D471/08 ,  A61K31/195 ,  A61K31/4709 ,  A61K31/485 ,  A61K31/49 ,  C07D221/28 ,  G01N33/49 ,  G01N33/493

摘要： This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

公开(公告)号：US20220313640A1

公开(公告)日：2022-10-06

申请号：US17614323

申请日：2020-05-29

申请人： Dario DOLLER ,  Christopher L. BRUMMEL ,  Julie F. LIU ,  Roger D. TUNG ,  Darren H. WONG ,  Tracey L. PETRYSHEN ,  Raymond S. HURST ,  Concert Pharmaceuticals, Inc.

发明人： Dario Doller ,  Christopher L. Brummel ,  Julie F. Liu ,  Roger D. Tung ,  Darren H. Wong ,  Tracey L. Petryshen ,  Raymond S. Hurst

IPC分类号： A61K31/198

摘要： This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

公开(公告)号：US20220213105A1

公开(公告)日：2022-07-07

申请号：US17400351

申请日：2021-08-12

申请人： Concert Pharmaceuticals, Inc.

发明人： Robert S. Lewis ,  Mahender Reddy Karla ,  Kathryn E. Kavouris ,  Yong Dong ,  Adam J. Morgan ,  Cameron J. Cowden

IPC分类号： C07D487/04

摘要： Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

公开(公告)号：US10039769B2

公开(公告)日：2018-08-07

申请号：US15610153

申请日：2017-05-31

申请人： Concert Pharmaceuticals, Inc.

发明人： Scott L. Harbeson

IPC分类号： A61K31/5517 ,  C07D487/04 ,  C07B59/00 ,  A61K45/06

摘要： This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.

公开(公告)号：US09944635B2

公开(公告)日：2018-04-17

申请号：US14958461

申请日：2015-12-03

申请人： Concert Pharmaceuticals, Inc.

发明人： Julie F. Liu ,  Scott L. Harbeson ,  Roger D. Tung

IPC分类号： C07D471/04 ,  C07B59/00 ,  A61K31/4184 ,  A61K31/4985

CPC分类号： C07D471/04 ,  A61K31/4184 ,  A61K31/4985 ,  C07B59/002 ,  Y02A50/411 ,  Y02A50/423

摘要： This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.

公开(公告)号：US09918987B2

公开(公告)日：2018-03-20

申请号：US15291764

申请日：2016-10-12

申请人： Concert Pharmaceuticals, Inc.

发明人： Roger D. Tung ,  Julie F. Liu ,  Scott L. Harbeson

IPC分类号： A61K31/522 ,  C07D473/06

CPC分类号： A61K31/522 ,  C07D473/06

摘要： This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

公开(公告)号：US20170258807A1

公开(公告)日：2017-09-14

申请号：US15610153

申请日：2017-05-31

申请人： Concert Pharmaceuticals, Inc.

发明人： Scott L. Harbeson

IPC分类号： A61K31/5517 ,  A61K45/06 ,  C07D487/04 ,  C07B59/00

CPC分类号： A61K31/5517 ,  A61K45/06 ,  C07B59/002 ,  C07B2200/05 ,  C07D487/04

摘要： This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.

公开(公告)号：US09540367B2

公开(公告)日：2017-01-10

申请号：US14422049

申请日：2013-08-15

申请人： Concert Pharmaceuticals, Inc.

发明人： Roger D. Tung

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P19/02 ,  A61P35/04 ,  A61P37/06 ,  C07D471/04 ,  A61P29/00 ,  A61P3/10

CPC分类号： A61K31/519 ,  A61P17/06 ,  A61P19/02 ,  C07B59/002 ,  C07B2200/05 ,  C07D471/04 ,  C07D487/04

摘要： The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

摘要翻译： 本发明在一个实施方案中提供式I化合物或其药学上可接受的盐，其中式I所示的变量如说明书中所定义。

公开(公告)号：US09512079B2

公开(公告)日：2016-12-06

申请号：US14921158

申请日：2015-10-23

申请人： Concert Pharmaceuticals, Inc.

发明人： Adam J. Morgan

IPC分类号： A61K31/44 ,  C07D215/56

CPC分类号： C07D215/56 ,  C07B59/002 ,  C07B2200/05

摘要： This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.